Scholarlink

Background <p>In the realm of critical care, cerebrovascular disease remains a major factor in patient morbidity and mortality, with limited treatment options outside of acute interventions. The importance of thiamine (vitamin B1) in energy metabolism is well-known, and it may provide neuroprotective benefits, though its role in serious cerebrovascular diseases is still uncertain.</p> Methods <p>Using data from the MIMIC-IV database, this retrospective cohort study explored the relationship between thiamine and short-term outcomes in patients with critical cerebrovascular conditions. The application of propensity score matching (PSM) helped to balance covariates between users and non-users of thiamine. The study’s primary and secondary endpoints were the all-cause mortality at 7, 14, and 28 days. To estimate hazard ratios (HR) and 95% confidence interval (CI), Cox proportional hazards models were used, along with analyses for subgroups, dose-response, and duration-response.</p> Results <p>Among 11,814 patients, 1,647 received thiamine. With 1,585 matched pairs post-PSM, thiamine administration showed a significant association with decreased mortality at 7 days (HR = 0.68, 95%CI: 0.53–0.89, <i>P</i> = 0.004), 14 days (HR = 0.78, 95%CI: 0.64–0.96, <i>P</i> = 0.016), and 28 days (HR = 0.82, 95%CI: 0.69–0.98, <i>P</i> = 0.028) compared with non-thiamine use after adjustment. Subgroup analyses revealed stronger benefits in patients aged ≥ 65 years, females, and those without mannitol or thrombolysis. Enhanced outcomes were most consistently observed with treatment durations longer than 5 days and daily doses lower than 100&#xa0;mg.</p> Conclusions <p>Thiamine supplementation correlated with a reduction in short-term mortality for patients with critical cerebrovascular conditions, especially with prolonged treatment and reduced daily doses. While these observations propose thiamine as a possible supportive metabolic therapy, the evidence remains insufficient to guide clinical practice and should be considered hypothesis-generating pending confirmation in randomized trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thiamine use and short-term prognosis in critical cerebrovascular disease: a propensity score matched retrospective analysis from the MIMIC-IV database

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月3日

查看全文
  • Tianli Zhang,
  • Minheng Zhang,
  • Haixia Fan,
  • Xuan Chen,
  • Peng Wei,
  • Zhaoxu Yin,
  • Xin Li

摘要

Background

In the realm of critical care, cerebrovascular disease remains a major factor in patient morbidity and mortality, with limited treatment options outside of acute interventions. The importance of thiamine (vitamin B1) in energy metabolism is well-known, and it may provide neuroprotective benefits, though its role in serious cerebrovascular diseases is still uncertain.

Methods

Using data from the MIMIC-IV database, this retrospective cohort study explored the relationship between thiamine and short-term outcomes in patients with critical cerebrovascular conditions. The application of propensity score matching (PSM) helped to balance covariates between users and non-users of thiamine. The study’s primary and secondary endpoints were the all-cause mortality at 7, 14, and 28 days. To estimate hazard ratios (HR) and 95% confidence interval (CI), Cox proportional hazards models were used, along with analyses for subgroups, dose-response, and duration-response.

Results

Among 11,814 patients, 1,647 received thiamine. With 1,585 matched pairs post-PSM, thiamine administration showed a significant association with decreased mortality at 7 days (HR = 0.68, 95%CI: 0.53–0.89, P = 0.004), 14 days (HR = 0.78, 95%CI: 0.64–0.96, P = 0.016), and 28 days (HR = 0.82, 95%CI: 0.69–0.98, P = 0.028) compared with non-thiamine use after adjustment. Subgroup analyses revealed stronger benefits in patients aged ≥ 65 years, females, and those without mannitol or thrombolysis. Enhanced outcomes were most consistently observed with treatment durations longer than 5 days and daily doses lower than 100 mg.

Conclusions

Thiamine supplementation correlated with a reduction in short-term mortality for patients with critical cerebrovascular conditions, especially with prolonged treatment and reduced daily doses. While these observations propose thiamine as a possible supportive metabolic therapy, the evidence remains insufficient to guide clinical practice and should be considered hypothesis-generating pending confirmation in randomized trials.